Summary
Dr. Mercola reconnects with Dr. Jason Sonners for a follow-up discussion on hyperbaric oxygen therapy, with Sonners now pursuing a PhD focused on regenerative medicine and hyperbaric research. The conversation goes deeper into the mechanisms of action, particularly the "hyperoxia-hypoxia paradox" described in Israeli research, which explains how HBOT provides the benefits of both high and low oxygen states without the downsides of chronic hypoxia. A major focus is the epigenetic and cellular signaling effects that occur when leaving the chamber. The relative hypoxia experienced post-session triggers HIF1-alpha, VEGF, BDNF, and stem cell responses while simultaneously upregulating sirtuins (longevity proteins) and increasing mitochondrial density and replication. This contrasts with true hypoxia, which would downregulate sirtuins and mitochondrial function. Sonners describes HBOT as fundamentally anabolic, stimulating growth, repair, and tissue regeneration. The episode also explores combining HBOT with fasting and exercise for enhanced autophagy, the role of molecular hydrogen as a selective antioxidant during HBOT, and Dr. Sonners' PhD research comparing 1.3 atmospheres versus 2.0 atmospheres across cytokine panels, methylation markers, and telomere measurements. They discuss practical protocols including Sonners' personal routine of two hours weekly with three intensive 30-40 hour blocks per year.
Key Points
- The hyperoxia-hypoxia paradox: HBOT provides benefits of hypoxia (stem cells, VEGF, HIF1-alpha) without the downsides (sirtuin and mitochondrial downregulation)
- Sirtuins (longevity proteins) are upregulated by HBOT, unlike true chronic hypoxia which suppresses them
- HBOT stimulates VEGF, BDNF, PDNF and other growth factors through relative hypoxia upon exiting the chamber
- Roughly half the therapeutic benefit occurs inside the chamber and half occurs after exiting as dissolved oxygen interacts with cells
- Molecular hydrogen is the preferred antioxidant companion to HBOT because it selectively triggers NRF2 without quenching beneficial free radical signaling
- PhD research comparing 1.3 vs 2.0 atmospheres will measure cytokines, methylation, and telomere length over 3-6 months
- Israeli research showed up to 20% increase in telomere length and reduction in senescent cells with specific HBOT protocols
- Personal protocol: two hours per week maintenance plus three intensive 30-40 hour blocks annually
Key Moments
HBOT mechanisms apply universally from gangrene to regenerative medicine
Dr. Jason Sonners argues that the mechanisms of action of hyperbaric therapy are the same regardless of condition, whether treating gangrene and radiation burns or pursuing regenerative medicine benefits, making the therapy broadly applicable.
"But my thought process is the mechanisms of action of hyperbaric are the same, whether we're talking about gangrene and radiation burns and osteonecrosis, as they are."
Comparing soft shell (1.3 atm) vs hard chamber (2.0 atm) effectiveness
Dr. Sonners describes his upcoming research comparing 1.3 atmosphere soft chamber protocols against 2.0 atmosphere hard chamber protocols, both with 100% oxygen, to determine if the more accessible soft chambers can produce meaningful clinical results.
"I want to build And so, what I'm doing is, I'm creating a study that's going to have a lower pressure group and a higher pressure group, and we're going to start comparing."
Half the therapy happens when you leave the chamber through relative hypoxia
Dr. Sonners explains that approximately half of HBOT's therapeutic benefit occurs after leaving the chamber, when the body experiences relative hypoxia as oxygen levels drop from supersaturated back to normal, triggering important cellular signaling cascades.
"I would say we don't have an exact number right now, but I might say something like, you know, roughly about half of the treatment benefit is coming while you are inside the chamber."
